Research focuses on (i) understanding the interplay between regulatory information encoded in the primary sequence of the human genome and epigenomic information inscribed by the joint action of trans-acting factors, chromatin remodelers, modifiers, and readers that yields a particular functional state in primary cells of the immune and central nervous systems; (ii) leveraging this understanding to engineer novel architectures for targeted epigenome editors customized for use in these and other clinically relevant human cell types; (iii) establishing preclinical proof-of-concept for the use of the resulting epigenome-editing molecular therapeutics in ex vivo and in vivo models of autoimmune and neurologic disease.

Repeat Rules